Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
Netflix and Amazon are struggling to win over the world's second-largest internet market

2018-07-06 theedgemarkets
(July 6): As Netflix and Amazon search for new users abroad, they are increasingly looking to India as a big market.
BALAJITELE FOX 532382 FOXA

0
Balaji Telefilms Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

0
Our focus is on premium drama: Applause’s Sameer Nair

2018-07-05 livemint
In less than a year of its launch, Aditya Birla Group chairman Kumar Mangalam Birla’s content studio Applause Entertainment already has about eight web shows in production, with many more awaiting announcement. The studio’s chief executive officer, Sameer Nair, who has seen the television and film landscape change with his earlier stints at the Star network and Balaji Telefilms, is looking at charting a digital-friendly future for audiences hungry for new-age content.
BALAJITELE 532382

0
Reliance launches fibre broadband, after disrupting India's telecoms market

2018-07-05 theedgemarkets
MUMBAI (July 5): Reliance Industries, which has upended India's telecoms sector with its cheap mobile data plans, launched its fibre broadband system on Thursday in a push to make deeper inroads into the country's wireless and fixed-line internet industry.
BALAJITELE 500325 BNPQY RELIANCE BNPQF BHRQY 533137 DEN 532454 BNPZY 532382 RIGD BHARTIARTL RLNIY

0
India's Reliance unveils fibre broadband service in 1,100 cities

2018-07-05 theedgemarkets
MUMBAI (July 5): Indian conglomerate Reliance Industries unveiled a fibre broadband system and said it will extend connectivity to 1,100 cities, stepping up its push to expand in the country's telecoms and internet services sector.
BALAJITELE 500325 532382 RELIANCE RIGD RLNIY

0
UPDATE 1-India's Reliance unveils fibre broadband service in 1,100 cities

2018-07-05 reuters
MUMBAI (Reuters) - Indian conglomerate Reliance Industries unveiled a fiber broadband system and said it will extend connectivity to 1,100 cities, stepping up its push to expand in the country’s telecoms and internet services sector.
BALAJITELE 500325 532382 RELIANCE RIGD RLNIY

0
18 Years of Kyunki Saas Bhi Kabhi Bahu Thi: Smriti Irani, Ekta Kapoor get nostalgic

2018-07-03 freepressjournal.in
Mumbai: “Kabhi Saas Bhi Kabhi Bahu Thi”, which began on this day 18 years ago, changed life for producer Ekta Kapoor and for actress Smriti Irani, who is now a Union Minister.
BALAJITELE 532382

0
Balaji Telefilms Limited - Updates

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

0
Balaji Telefilms Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

0
Balaji Telefilms Limited - ESOP/ESOS/ESPS

2018-06-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BALAJITELE 532382

0
Apara Mehta excited about her comeback

2018-06-04 freepressjournal.in
Apara Mehta has been roped in for upcoming fantasy TV show “Qayamat Ki Raat”. Apara, who famously played Savita Mansukh Virani in the iconic Hindi television show “Kyunki Saas Bhi Kabhi Bahu Thi”, is excited about the role.
BALAJITELE 532382

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

10h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

11h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...